

World Psoriasis Day 2021

Almirall launches "Shedding Light on Psoriasis" campaign to raise awareness on World Psoriasis Day

- The campaign aims to raise awareness on how psoriasis deeply impacts the wellbeing of people living with this long-term condition and their families
- Psoriasis represents a significant burden in the daily life of 71% of psoriasis patientsⁱ and affects the overall emotional wellbeing of 88% of themⁱⁱ
- Four out of ten patients with psoriasis have seen their disease worsen during the Covid-19 pandemic

BARCELONA, Spain. October 28th, 2021 – Almirall, a global biopharmaceutical company focused on skin health and an active partner of the International Federation for Psoriasis Associations (IFPA) is launching the campaign “Shedding Light on Psoriasis” in support of World Psoriasis Day 2021, which is celebrated on October, 29th, to raise awareness about the daily challenges faced by people living with psoriasis and to highlight the importance of ensuring their wellbeing.

Psoriasis is one of the world's most prevalent skin diseases, affecting about 60 million people worldwideⁱⁱⁱ. Almirall's campaign “Shedding Light on Psoriasis” aims to point out the need to shed light on a condition with high unmet needs.



More information can be found at www.almirall.com/world-psoriasis-day

Almirall is also a proud sponsor of IFPA's World Psoriasis Day campaign in 2021, "United - Now act", aims to unite the psoriatic disease community to demand action in order to change the perception of the condition, ensure equal access to treatment, stop stigmatization, advance holistic care, and prepare the health workforce to manage this complex and chronic condition. With the launch of this initiative, the IFPA concludes its three-year campaign "Connected, Informed, United" that began in 2019.

The hidden face of psoriasis: its impact on wellbeing

There is a well-established relationship between psoriasis and mental health comorbidity. Psoriasis represents a significant burden in the daily life of 71% of patients¹ and it is also reported that it affects the overall emotional wellbeing of 88% of patients.² They perceive their relationship with healthcare professionals to be linked not only to the management of their disease, but also to their happiness and wellbeing^{iv}. Furthermore, the visibility of psoriasis can cause social rejection and a sense of stigmatization that can negatively affect the person's work life and his or her social relationships.

People living with psoriasis may find that symptoms such as itching, scaling, and discoloration worsen during times of stress. Furthermore, the COVID-19 pandemic, which, in the case of psoriasis led into cancelled appointments and an initial hesitancy to start immunomodulatory therapy, may result in long-lasting consequences. According to recent data published in the Journal of The European Academy of Dermatology and Venereology, 43% of people living with psoriatic disease report that their condition has worsened during the COVID-19 pandemic.

About Psoriasis Vulgaris

Psoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques. Psoriasis affects people of all ages, and in all countries. The reported prevalence of psoriasis in Europe varies from 0.6% to 6.5% with an average of approximately 3% of the population^{v,vi}, making psoriasis a serious global problem with about 60 million individuals affected worldwideⁱⁱⁱ. The flares of psoriasis can be unpredictable and significant comorbidities are common, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com

Media contact:

Tinkle
Pilar Colomer
pcolomer@tinkle.es
Phone: (+34) 93 545 12 51

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Maria Duro
maria.duro@almirall.com
Phone: (+34) 671 580 492

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication, click [here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.

ⁱ National Psoriasis Foundation 2008 Survey Snapshot. Available from: <http://www.psoriasis.org/document.doc?id=193>

ⁱⁱ Armstrong AW, Schupp C, Wu J, et al. PLoS One. 2012;7(12):e52935; 2. National Psoriasis Foundation 2008 Survey Snapshot. Available from: <http://www.psoriasis.org/document.doc?id=193>; 3. Krueger G, Koo J, Lebwohl M, et al. Arch Dermatol. 2001;137(3):280-284.

ⁱⁱⁱ Parisi R, Iskandar I Y K, Kontopantelis E, Augustin M, Griffiths C E M, Ashcroft D M et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study BMJ 2020; 369 :m1590 doi:10.1136/bmj.m1590

^{iv} Source: International Federation of Psoriasis Associations. Oct 2021. <https://ifpa-pso.com/>

^v Chandran, V., and S.P. Raychaudhuri. 2010. 'Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis', J. Autoimmune, 34: J314-J21

^{vi} Schafer, T. 2006. 'Epidemiology of psoriasis. Review and the German perspective', Dermatology, 212: 327-37